Neoadjuvant chemotherapy with gemcitabine and S-1 for resectable and borderline pancreatic ductal adenocarcinoma: A prospective, multi-institutional, phase II trial

被引：2
|
作者：
Mizuma, Masamichi
Motoi, Fuyuhiko
Ishida, Kazuyuki
Fujishima, Fumiyoshi
Ottomo, Shigeru
Oikawa, Masaya
Okada, Takaho
Shimamura, Hiromune
Takemura, Shinichi
Ono, Fuminori
Akada, Masanori
Nakagawa, Kei
Katayose, Yu
Egawa, Shinichi
Unno, Michiaki
机构：
[1] Tohoku Univ, Grad Sch Med, Dept Surg, Sendai, Miyagi 980, Japan
[2] Iwate Med Univ, Dept Mol Diagnosit Pathol, Morioka, Iwate 020, Japan
[3] Tohoku Univ, Grad Sch Med, Dept Pathol, Sendai, Miyagi 980, Japan
[4] Sendai Open Hosp, Sendai, Miyagi, Japan
[5] Sendai Med Ctr, Sendai, Miyagi, Japan
[6] Shirakawa Kousei Hosp, Shirakawa, Japan
[7] Senboku Kumiai Gen Hosp, Dept Surg, Daisen, Japan
[8] South Miyagi Med Ctr, Dept Surg, Ogawara, Japan
[9] Tohoku Univ, Grad Sch Med, Div Integrated Surg & Oncol, Sendai, Miyagi 980, Japan
[10] Tohoku Univ, Int Res Inst Disaster Sci, Sendai, Miyagi 980, Japan
[11] Tohoku Univ, Sch Med, Sendai, Miyagi 980, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 03期
关键词：
D O I：
10.1200/jco.2014.32.3_suppl.283
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
283
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A Prospective, Open-Label, Multicenter Phase 2 Trial of Neoadjuvant Therapy Using Full-Dose Gemcitabine and S-1 Concurrent with Radiation for Resectable Pancreatic Ductal Adenocarcinoma
    Eguchi, Hidetoshi
    Takeda, Yutaka
    Takahashi, Hidenori
    Nakahira, Shin
    Kashiwazaki, Masaki
    Shimizu, Junzo
    Sakai, Daisuke
    Isohashi, Fumiaki
    Nagano, Hiroaki
    Mori, Masaki
    Doki, Yuichiro
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (13) : 4498 - 4505
  • [32] Phase II trial of neoadjuvant S-1 and concurrent radiotherapy for borderline resectable pancreatic cancer (JASPAC05)
    Ohno, Izumi
    Takahashi, Shinichiro
    Kobayashi, Tatsushi
    Akimoto, Tetsuo
    Toyama, Hirochika
    Shimizu, Yasuhiro
    Morinaga, Soichiro
    Nakamori, Shoji
    Hishinuma, Shoichi
    Takakura, Norihisa
    Takayama, Wataru
    Hirano, Satoshi
    Otsubo, Takehito
    Ikeda, Masafumi
    Uesaka, Katsuhiko
    ANNALS OF ONCOLOGY, 2018, 29
  • [33] A phase I study of neoadjuvant chemotherapy with gemcitabine plus oral S-1 for resectable pancreatic cancer
    Tajima, Hidehiro
    Kitagawa, Hirohisa
    Tsukada, Tomoya
    Nakanuma, Shinich
    Okamoto, Koichi
    Sakai, Seisho
    Makino, Isamu
    Furukawa, Hiroyuki
    Nakamura, Keishi
    Hayashi, Hironori
    Oyama, Katsunobu
    Inokuchi, Masafumi
    Nakagawara, Hisatoshi
    Miyashita, Tomoharu
    Fujita, Hideto
    Itoh, Hiroshi
    Takamura, Hiroyuki
    Ninomiya, Itasu
    Fushida, Sachio
    Fujimura, Takashi
    Ohta, Tetsuo
    MOLECULAR AND CLINICAL ONCOLOGY, 2013, 1 (04) : 768 - 772
  • [34] Neoadjuvant chemotherapy for resectable adenocarcinoma of the panctreatic head - a prospective phase II trial
    Pestalozzi, B. C.
    Heinrich, S.
    Schafer, M.
    Pierre-Alain, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [35] Survival impact of neoadjuvant gemcitabine plus S-1 chemotherapy for patients with borderline resectable pancreatic carcinoma with arterial contact
    Murakami, Yoshiaki
    Uemura, Kenichiro
    Sudo, Takeshi
    Hashimoto, Yasushi
    Kondo, Naru
    Nakagawa, Naoya
    Takahashi, Shinya
    Sueda, Taijiro
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (01) : 37 - 47
  • [36] Survival impact of neoadjuvant gemcitabine plus S-1 chemotherapy for patients with borderline resectable pancreatic carcinoma with arterial contact
    Yoshiaki Murakami
    Kenichiro Uemura
    Takeshi Sudo
    Yasushi Hashimoto
    Naru Kondo
    Naoya Nakagawa
    Shinya Takahashi
    Taijiro Sueda
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 37 - 47
  • [37] Outcomes of neoadjuvant gemcitabine plus S-1 and radiation therapy for borderline resectable pancreatic cancer
    Yabushita, Yasuhiro
    Matsuyama, Ryusei
    Miyake, Kentaro
    Homma, Yuki
    Kumamoto, Takafumi
    Misumi, Toshihiro
    Hata, Masaharu
    Yamanaka, Shoji
    Fujii, Satoshi
    Endo, Itaru
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SCIENCES, 2023, 30 (04) : 493 - 502
  • [38] Predictors of Poor Pathological Response to Neoadjuvant Gemcitabine Plus S-1 Chemotherapy in Patients With Pancreatic Ductal Adenocarcinoma
    Mori, Shozo
    Aoki, Taku
    Sakuraoka, Yuhki
    Shimizu, Takayuki
    Yamaguchi, Takamune
    Park, Kyung-Hwa
    Matsumoto, Takatsugu
    Shiraki, Takayuki
    Iso, Yukihiro
    Kubota, Keiichi
    PANCREAS, 2021, 50 (05) : 744 - 750
  • [39] Pilot study of neoadjuvant chemotherapy with gemcitabine and oral S-1 for resectable pancreatic cancer
    Tajima, Hidehiro
    Ohta, Tetsuo
    Kitagawa, Hirohisa
    Okamoto, Koichi
    Sakai, Seisho
    Makino, Isamu
    Kinoshita, Jun
    Furukawa, Hiroyuki
    Nakamura, Keishi
    Hayashi, Hironori
    Oyama, Katsunobu
    Inokuchi, Masafumi
    Nakagawara, Hisatoshi
    Fujita, Hideto
    Takamura, Hiroyuki
    Ninomiya, Itasu
    Fushida, Sachio
    Tani, Takashi
    Fujimura, Takashi
    Ikeda, Hiroko
    Kitamura, Seiko
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2012, 3 (05) : 787 - 792
  • [40] Neoadjuvant phase II trial of chemo-radiotherapy (CRT) in patients with resectable (R) and borderline resectable (BR) pancreatic ductal adenocarcinoma (PDA)
    Damarla, V.
    Dobrosotskaya, D.
    Siddiqui, F.
    Wollner, I.
    Raoufi, M.
    Li, J.
    Kwon, D.
    Khan, G.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S8 - S9
12345